Skip to main content
Clinical Trials/NCT07058987
NCT07058987Not yet recruitingNot Applicable

A Prospective Randomized Controlled Study on the Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation on Cardiac Function and Exercise Capacity in Patients With Atrial Fibrillation

Lanzhou University Second Hospital1 site in 1 country200 target enrollmentStarted: July 15, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
200
Locations
1
Primary Endpoint
Change in Left Ventricular Ejection Fraction (LVEF) from Baseline to Week 12

Study Overview

Brief Summary

This is a prospective randomized controlled trial designed to evaluate the effectiveness of enhanced external counterpulsation (EECP) combined with cardiac rehabilitation in patients with atrial fibrillation. The study aims to assess whether this combined intervention can improve cardiac function and exercise capacity compared to standard care alone. Eligible participants will be randomly assigned to receive either the EECP plus cardiac rehabilitation program or routine treatment. Primary outcomes include changes in left ventricular ejection fraction (LVEF) and six-minute walking distance (6MWD). The study will be conducted at Lanzhou University Second Hospital.

Detailed Description

Atrial fibrillation (AF) is a common cardiac arrhythmia associated with impaired ventricular function, reduced exercise tolerance, and increased risk of cardiovascular events. While pharmacological treatments and catheter ablation are widely used, non-pharmacological interventions such as enhanced external counterpulsation (EECP) and cardiac rehabilitation (CR) may offer additional benefits for improving cardiac performance and quality of life. This prospective, single-center, randomized controlled trial aims to evaluate the effects of EECP combined with a structured cardiac rehabilitation program in patients with persistent or paroxysmal atrial fibrillation. A total of approximately 200 eligible participants will be randomized in a 1:1 ratio to receive either EECP plus cardiac rehabilitation (intervention group) or routine medical care (control group) for a defined treatment period. The cardiac rehabilitation program will include individualized exercise training, health education, risk factor management, and follow-up support. EECP will be performed according to standard protocols for cardiovascular patients. Primary outcome measures will include changes in left ventricular ejection fraction (LVEF) and six-minute walking distance (6MWD) from baseline to the end of the intervention. Secondary outcomes may include assessments of quality of life, symptoms, and biomarkers. Safety and feasibility will also be recorded. This study is expected to provide clinical evidence supporting the integration of EECP and cardiac rehabilitation as a non-invasive, multidimensional treatment approach in patients with atrial fibrillation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
40 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age between 40 and 80 years
  • •Diagnosed with persistent or paroxysmal atrial fibrillation, confirmed by ECG or Holter
  • •Stable medical condition and able to participate in cardiac rehabilitation and EECP therapy
  • •Provided written informed consent

Exclusion Criteria

  • •Recent acute myocardial infarction, unstable angina, or decompensated heart failure within the past 4 weeks
  • •Severe valvular heart disease or left ventricular ejection fraction <30%
  • •Severe peripheral vascular disease or deep vein thrombosis
  • •Severe pulmonary disease or active infection
  • •History of bleeding disorders or contraindications to EECP
  • •Cognitive impairment or psychiatric condition affecting study participation
  • •Participation in another clinical trial within the past 3 months

Arms & Interventions

EECP + Cardiac Rehabilitation

Experimental

Participants will receive enhanced external counterpulsation (EECP) plus a structured cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support and lifestyle counselling.

Intervention: Cardiac Rehabilitation Combined With EECP (Behavioral)

Routine Medical Care

Active Comparator

Participants will continue to receive standard pharmacologic management and routine clinical follow-up for atrial fibrillation without EECP or formal cardiac rehabilitation.

Intervention: Routine Medical Care (Other)

Outcomes

Primary Outcomes

Change in Left Ventricular Ejection Fraction (LVEF) from Baseline to Week 12

Time Frame: Baseline and 12 weeks after intervention

LVEF will be assessed using transthoracic echocardiography to evaluate improvement in systolic cardiac function.

Secondary Outcomes

  • Incidence of Adverse Events(Throughout the 12-week intervention period)
  • Change in NT-proBNP Level(Baseline and 12 weeks)
  • Change in 6-Minute Walk Distance (6MWD)(Baseline and 12 weeks)
  • Incidence of Adverse Events(Throughout the 12-week intervention period)
  • Change in NT-proBNP Level(Baseline and 12 weeks)
  • Change in Health-Related Quality of Life (HRQoL) Measured by SF-36 Total Score(Baseline and 12 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Xiaowei Zhang

lanzhou university second hospital

Lanzhou University Second Hospital

Study Sites (1)

Loading locations...

Similar Trials